Carregant...
Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature
Cetuximab is an approved treatment for metastatic colorectal carcinoma (mCRC) with codon 12/13-KRAS mutations, recently questioned for its validity, and alternative mutation-based biomarkers were proposed. We set out to investigate whether an expression signature can also predict response by utilizi...
Guardat en:
| Publicat a: | Oncotarget |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Impact Journals LLC
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5226604/ https://ncbi.nlm.nih.gov/pubmed/27409671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10499 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|